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We retrospectively analyzed the performance of the Architect HIV antigen/antibody (Ag/Ab) combination
assay in a tertiary health care center with a situation of low HIV prevalence. The specificity and positive
predictive value (PPV) were 99.78% and 31.21%, respectively. However, the specificity and PPV could increase
to 99.99% and 89.70% using an arbitrary cutoff value.
Since the first HIV test was introduced in 1985, the perfor-
mances of HIV screening assays have improved continuously.
In particular, the HIV antigen/antibody (Ag/Ab) combination
assays launched in 1997 have shortened the window period by
4 to 5 days compared to those of the previous antibody-alone
enzyme immunoassays (8). After the improvement of the de-
tection limit of the p24 antigen enzyme immunoassay (EIA) to
equivalent to that of the single-antigen EIA, HIV Ag/Ab com-
bination assays have been implemented in numerous labora-
tories throughout the world (7, 9).
The Centers for Disease Control and Prevention (CDC)
recommended the expansion of HIV antibody testing from
targeted, risk-based testing to universal screening of all adults
aged 13 to 64 years in health care settings (2). Although the
revised recommendation could be effective in identifying the
maximum possible number of HIV-infected people from a
public health perspective, there are concerns about false-pos-
itive results (3, 11). False-positive HIV screening results could
cause substantial psychological distress while waiting for a con-
firmatory test (10). Guinn estimated the positive predictive
value (PPV) of rapid HIV testing in Oregon with 100% sen-
sitivity and 99.9% specificity to be 29% (3). The rate of false-
positive results could be dramatically increased in situations of
extremely low HIV prevalence. Shima-Sano et al. reported that
the PPV of HIV screening results in pregnant women is only
3.7% (5).
According to a report by the Korea Centers for Disease
Control and Prevention, 6,120 individuals have been diagnosed
with an HIV infection between 1985 and 2008 in Korea (4).
Although the number of newly diagnosed HIV infections has
increased, the cumulative number of HIV-infected individuals
and prevalence were lower than those in other countries.
There has been limited study on the rate of false-positive
results in HIV screening tests using an automated HIV Ag/Ab
combination assay. In the present study, we retrospectively
analyzed the performance of an automated HIV Ag/Ab com-
bination assay in a tertiary health care center with a situation
of low HIV prevalence.
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TABLE 1. Specificities and positive predictive values of the Architect HIV Ag/Ab combination assaya
Parameter
Value(s) for assay group
Male Female Total
Total no. tested 77,708 77,631 155,339
No. of positive initial screening test results (%) 342 (0.440) 201 (0.259) 543 (0.350)
No. of false-positive results (%) 153 (0.197) 193 (0.249) 346 (0.223)
No. of indeterminate results (%) 4 (0.005) 0 (0.000) 4 (0.003)
No. of true HIV-positive results (%) 152 (0.196) 5 (0.006) 157 (0.101)
No. of previously confirmed HIV-positive results (%) 33 (0.042) 3 (0.004) 36 (0.023)
Specificity (%) 99.80 99.75 99.78
95% confidence interval (%) 99.77–99.83 99.71–99.79 99.75–99.80
Positive predictive value (%) 49.84 2.53 31.21
95% confidence interval (%) 44.09–55.59 0.83–5.80 27.22–35.49
a Tests with indeterminate results and previously HIV-confirmed samples were excluded in statistical analysis.
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During the period of 1 January 2006 through 31 December
2009, a total of 155,339 samples were tested for HIV using
Architect HIV Ag/Ab Combo (HIV Combo; Abbott Labora-
tories, Abbott Park, IL) in a university hospital in South Korea.
The Architect HIV Combo test was performed with an auto-
mated random access instrument (Architect i2000; Abbott
Laboratories) throughout the study period. HIV Combo is a
microparticle-based chemiluminescent immunoassay, designed
for the simultaneous detection of HIV p24 antigen and HIV-1
and HIV-2 antibodies. Assay results were presented as ratios
of specimen signals to the cutoff values (S/CO), where an S/CO
ratio greater than or equal to 1.00 is considered reactive. The
assays were performed according to the manufacturer’s direc-
tions.
Specimens that initially tested reactive were retested in du-
plicate, and repeatedly reactive specimens were subjected to a
secondary screening test and confirmatory test. The Vitros
anti-HIV 12 assay on the Vitros ECiQ immunodiagnostic
system (Ortho Clinical Diagnostics, Raritan, NJ) was used as a
secondary screening test. Due to the low sample volume, sec-
ondary screening assays were performed with 403 specimens
among 507 repeatedly reactive specimens. Repeatedly reactive
specimens were confirmed by Western blotting (WB) (HIV
Blot version 2.2; Genelabs Diagnostics, Singapore) at the Ko-
rean National Institute of Health, Seoul, South Korea. Statis-
tical analysis was performed using SPSS version 12.0 for Win-
dows (SPSS Inc., Chicago, IL). This study was approved by the
institutional review board of Yonsei University Health System.
A total of 155,339 HIV screening tests for 132,934 patients
were performed during the past 4 years; the median patient
age was 42.6 years (range, 0 months to 97 years). As shown in
Table 1, 543 (0.350%) specimens were found to be reactive
using the initial HIV Combo screening assay and repeatedly
reactive using the duplicated retesting. By review of the previ-
ous laboratory results, 36 specimens were collected from pre-
viously confirmed HIV-infected individuals and excluded from
supplementary testing such as secondary screening testing or
WB analysis. The HIV antibody was confirmed in 157 speci-
mens by WB, and 346 specimens were concluded to have
false-positive results, corresponding to a specificity of 99.78%
(exact binomial 95% confidence interval [CI], 99.75% to
99.80%). However, PPVs were significantly different between
genders, as follows: 49.84% (95% CI, 44.09% to 55.59%) for
males and 2.53% (95% CI, 0.83% to 5.80%) for females. These
results could be explained by the epidemiologic characteristics
of HIV infection in South Korea, showing that approximately
92% of HIV-infected individuals were male.
The mean S/CO ratio of false-positive results was 2.94
(range, 1.00 to 34.59) and that of HIV-positive specimens by
WB was 385.97 (range, 7.28 to 739.98) (Fig. 1). The optimal
cutoff value based on the highest sum of sensitivity and spec-
ificity was estimated to be 8.8, but assay sensitivity was lowered
to 99.36% using this cutoff value. With the sensitivity adhering
to 100%, the optimal cutoff was revised to 6.6. Using this cutoff
value, the assay specificity and PPV were increased to 99.99%
(95% CI, 99.98% to 99.99%) and 89.70% (95% CI, 84.00% to
93.62%), respectively (Table 2).
By simply combining the results from the secondary screen-
ing test with those from the initial screening test (cutoff, 1.0),
the specificity and PPV were increased to 99.99% (95% CI,
99.992% to 99.999%) and 94.44% (95% CI, 85.65% to
98.21%), respectively. Furthermore, by combining the results
from the secondary test with those from the initial screening
FIG. 1. Distribution of the S/CO ratios of HIV-positive screening
samples, according to the results obtained by Western blotting.
TABLE 2. Performance of the Architect HIV Ag/Ab combination assay according to cutoff S/CO ratios
Parameter Value(s) based on cutoff S/CO ratio
Value of cutoff S/CO ratio 1.0 6.6 8.8
No. of positive initial screening test results (%) 543 (0.350) 216 (0.139) 209 (0.135)
No. of false-positive results (%) 346 (0.223) 19 (0.012) 13 (0.012)
No. of indeterminate results (%) 4 (0.003) 4 (0.003) 4 (0.003)
No. of true HIV-positive results (%) 157 (0.101) 157 (0.101) 156 (0.100)
No. of previously confirmed HIV-positive results (%) 36 (0.023) 36 (0.023) 36 (0.023)
Specificity (%) 100.00 100.00 99.36
95% confidence interval (%) 97.02–100.00 97.02–100.00 95.97–99.97
Positive predictive value (%) 99.78 99.99 99.99
95% confidence interval (%) 99.75–99.80 99.98–99.99 99.99–99.99
No. of true HIV-positive results (%) 31.21 89.70 92.31
No. of previously confirmed HIV results (%) 27.22–35.49 84.00–93.62 86.93–95.67
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test using the revised cutoff value of 6.6, there were no false-
positive results.
With numerous technical improvements, the current sero-
logical HIV screening assays were very sensitive compared to
the early immunoassay detecting the HIV antibody. Since
2001, new “fourth-generation” HIV tests designed to detect
both HIV p24 antigen and antibody in a single immunoassay
have shortened the diagnostic window with additional sensitive
HIV antigen tests. Currently, these new fourth-generation as-
says are widely used for routine laboratory diagnosis of HIV.
Assay specificity is another important point to consider, and
Weber determined the specificity of fourth-generation HIV
assays launched after 2001 to be between 99.50% and 99.90%
(6). Our study using the Architect HIV Combo assay showed
comparable results (specificity, 99.78%; 95% CI, 99.75% to
99.80%).
Even with higher specificity, a low PPV (31.21%; 95% CI,
27.22% to 35.49%) is problematic in situations of low HIV
prevalence. In our study, the PPV for males (49.84%; 95%
CI, 44.09% to 55.59%) was significantly higher than that for
females (2.53%; 95% CI, 0.83% to 5.80%), reflecting the
difference of disease prevalence between genders. If 1 mil-
lion specimens from each gender under the same conditions
of prevalence are tested, approximately 1,970 and 2,490
results will be reported falsely positive from males and fe-
males, respectively. As the CDC recommended supplemen-
tal testing algorithms of antibody to hepatitis C virus for
S/CO ratios (1), we could improve the PPV of the HIV
Combo assay from 33.21% to 89.20% by setting up an arbi-
trary revised cutoff S/CO ratio of 6.6. This means that the
number of false-positive results will reduce from 346 to only
19 without any further testing. If the secondary screening
test is incorporated, the number of false-positive results
could be significantly reduced.
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